<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04915781</url>
  </required_header>
  <id_info>
    <org_study_id>THL/713/6.00.00/2021</org_study_id>
    <nct_id>NCT04915781</nct_id>
  </id_info>
  <brief_title>Tobacco Use and COVID-19 Incidence in the Finnish General Population</brief_title>
  <acronym>Tobrisk-CoV</acronym>
  <official_title>Tobacco Use and Incidence of SARS-CoV-2 Infection in the Finnish General Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Finnish Institute for Health and Welfare</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Norwegian Institute of Public Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Finnish Institute for Health and Welfare</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational study of participants in three general population health surveys&#xD;
      (FinSote 2018, 2019, 2020) who are followed up until the incidence of SARS-CoV-2 infection or&#xD;
      end of follow-up. The primary objective is to examine the association between tobacco use and&#xD;
      the risk of SARS-CoV-2 infection in a general population sample in Finland.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tobacco use, as a leading risk factor of death and disability due to respiratory diseases,&#xD;
      was expected to increase the risk of SARS-CoV-2 infection and COVID-19 deaths. Earlier&#xD;
      epidemiological studies, however, showed that smokers were underrepresented among patients&#xD;
      hospitalized due to COVID-19. The most recent meta-analysis has confirmed these early&#xD;
      findings, showing that current smokers had lower risk of SARS-CoV-2 infection than never&#xD;
      smokers (Relative risk 0.71, 95% Credible interval 0.61; 0.82). A majority of these studies&#xD;
      are based on samples of hospitalized patients, tested population or specific population&#xD;
      groups, which might not represent the general population. In addition, data on tobacco use&#xD;
      has been primarily collected from electronic health records or retrospectively and therefore&#xD;
      prone to misclassification and information bias.&#xD;
&#xD;
      A message of a protective effect of tobacco use could undermine public health efforts to curb&#xD;
      its use and reduce the perception of harm in the general population. Studies with general&#xD;
      population samples and prospective data collection are thus urgently needed.&#xD;
&#xD;
      The aim of the study is to examine the association between tobacco use and the risk of&#xD;
      SARS-CoV-2 infection. We will explore several forms of tobacco use (smoking, moist smokeless&#xD;
      tobacco and e-cigarettes) and investigate whether introducing a potential collider bias by&#xD;
      adjusting for mediating risk factors (alcohol use, physical activity and obesity) could have&#xD;
      explained earlier results. We will use data from a prospective cohort study of nationally&#xD;
      representative health surveys in Finland linked to SARS-CoV-2 incidence data, which is less&#xD;
      subject to collider and recall bias than previous case-control studies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 2, 2017</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of SARS-CoV-2 infection</measure>
    <time_frame>Baseline until SARS-CoV-2 infection or April 30, 2021</time_frame>
    <description>Incidence is the detection of a new SARS-CoV-2 infection with RT-PCR or a COVID-19 syndrome diagnosed by a physician from baseline to April 30, 2021</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">60872</enrollment>
  <condition>SARS-CoV-2 Infection</condition>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Tobacco users</arm_group_label>
    <description>Never smokers (reference group) will be compared with former smokers, occasional smokers and daily smokers. For FinSote 2018 and 2020, we will also compare never users of (1) smokeless tobacco (snus), (2) electronic cigarettes with and without nicotine or (3) nicotine replacement therapy products with respective former, occasional and daily users.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Not applicable, this is an observational study</intervention_name>
    <description>Not applicable, this is an observational study</description>
    <arm_group_label>Tobacco users</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Permanent residents in Finland aged 20 and over who participated in the FinSote surveys in&#xD;
        2018, 2019 and 2020. These are general population samples representative of the Finnish&#xD;
        population. The sampling frame was the Population Register (in 2020 the Digital and&#xD;
        Population Data Services Agency, created after the merge between the Population Register of&#xD;
        Statistics Finland and local register offices), which includes all individuals residing&#xD;
        permanently in Finland, including conscripts and people living in institutions.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Permanent residents of Finland&#xD;
&#xD;
          -  Registered in the Population Register at the moment of sampling&#xD;
&#xD;
          -  Aged 20 and over&#xD;
&#xD;
          -  Participated in the FinSote surveys in 2018, 2019 or 2020&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Temporary residents in Finland or tourists&#xD;
&#xD;
          -  Age less than 20 years old&#xD;
&#xD;
          -  Did not participate in FinSote surveys in 2018, 2019 and 2020&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sakari Karvonen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Finnish Institute for Health and Welfare</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Finland</name>
      <address>
        <city>Helsinki</city>
        <zip>00271</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <link>
    <url>https://www.nordforsk.org/projects/addressing-smoking-paradox-etiology-covid-19-through-population-based-studies-tobrisk-cov</url>
    <description>Description of the Tobrisk-CoV project</description>
  </link>
  <reference>
    <citation>Simons D, Shahab L, Brown J, Perski O. The association of smoking status with SARS-CoV-2 infection, hospitalization and mortality from COVID-19: a living rapid evidence review with Bayesian meta-analyses (version 7). Addiction. 2021 Jun;116(6):1319-1368. doi: 10.1111/add.15276. Epub 2020 Nov 17. Review.</citation>
    <PMID>33007104</PMID>
  </reference>
  <reference>
    <citation>Bar-Zeev Y. Commentary on Simons et al. Public health implications of the suggested association between nicotine, smoking and infection with SARS-CoV-2. Addiction. 2021 Jun;116(6):1369-1370. doi: 10.1111/add.15356. Epub 2020 Dec 25.</citation>
    <PMID>33368844</PMID>
  </reference>
  <reference>
    <citation>Griffith GJ, Morris TT, Tudball MJ, Herbert A, Mancano G, Pike L, Sharp GC, Sterne J, Palmer TM, Davey Smith G, Tilling K, Zuccolo L, Davies NM, Hemani G. Collider bias undermines our understanding of COVID-19 disease risk and severity. Nat Commun. 2020 Nov 12;11(1):5749. doi: 10.1038/s41467-020-19478-2.</citation>
    <PMID>33184277</PMID>
  </reference>
  <reference>
    <citation>Haddad C, Bou Malhab S, Sacre H, Salameh P. Smoking and COVID-19: A Scoping Review. Tob Use Insights. 2021 Feb 15;14:1179173X21994612. doi: 10.1177/1179173X21994612. eCollection 2021. Review.</citation>
    <PMID>33642886</PMID>
  </reference>
  <reference>
    <citation>Tattan-Birch H, Marsden J, West R, Gage SH. Assessing and addressing collider bias in addiction research: the curious case of smoking and COVID-19. Addiction. 2021 May;116(5):982-984. doi: 10.1111/add.15348. Epub 2021 Jan 20.</citation>
    <PMID>33226690</PMID>
  </reference>
  <reference>
    <citation>van Westen-Lagerweij NA, Meijer E, Meeuwsen EG, Chavannes NH, Willemsen MC, Croes EA. Are smokers protected against SARS-CoV-2 infection (COVID-19)? The origins of the myth. NPJ Prim Care Respir Med. 2021 Feb 26;31(1):10. doi: 10.1038/s41533-021-00223-1. Review.</citation>
    <PMID>33637750</PMID>
  </reference>
  <reference>
    <citation>Vardavas CI, Nikitara K. COVID-19 and smoking: A systematic review of the evidence. Tob Induc Dis. 2020 Mar 20;18:20. doi: 10.18332/tid/119324. eCollection 2020.</citation>
    <PMID>32206052</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 3, 2021</study_first_submitted>
  <study_first_submitted_qc>June 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2021</study_first_posted>
  <last_update_submitted>June 4, 2021</last_update_submitted>
  <last_update_submitted_qc>June 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tobacco use</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>COVID-19</keyword>
  <keyword>Epidemiology</keyword>
  <keyword>Cohort Studies</keyword>
  <keyword>Incidence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Researchers can access individual data by contacting the Responsible Researcher at the Finnish Institute for Health and Welfare, Suvi Parikka, suvi.parikka [at] thl.fi.&#xD;
Information about FinSote surveys, including questionnaires, can be found in https://thl.fi/fi/tutkimus-ja-kehittaminen/tutkimukset-ja-hankkeet/finsote-tutkimus</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 2, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/81/NCT04915781/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

